Health & Biotech
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
Race’s lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.
Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia (AML).
Race is investigating the effect of bisantrene on the m6A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m6A RNA pathway has been described in numerous peer reviewed studies to be a driver of a diverse range of cancers.
Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.
Learn more at www.raceoncology.com.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Fisher & Paykel Healthcare shares tumble after Trump tariff king-hit
Health & Biotech
ASX Quarterly Health Wrap: Blinklab starts key FDA study, Mach 7 set to meet FY25 guidance
Stockhead TV
Road to 2025: Race on track with clinical trials
Health & Biotech
Biocurious: Behind Race Oncology’s quest to prevent chemo from being worse than the disease
News
Closing Bell: ASX slips as Fed decision looms
Health & Biotech
Race Oncology bolsters leadership with key appointment
News
ASX Lunch Wrap: ASX in upbeat mood; Bitcoin marches higher amid US reserve plans
News
Closing Bell: Tough going for the ASX on Friday ahead of US jobs report; Bitcoin cools off
Health & Biotech
Race submits key ethics application for phase I cancer trial
Stockhead TV
Long Shortz with Race Oncology: collaboration with Monash University
Health & Biotech
Health Check: Actinogen powers ahead with key Alzheimer’s disease trial
Health & Biotech
ASX Quarterly Health Wrap: Regulatory wins and record revenue
News
Closing Bell: Energy stocks cushion ASX’s mini crash; Infinity soars on Cangai copper acquisition
News
ASX Small Caps Lunch Wrap: Geopolitical turmoil still suppressing markets… buy the dip?
Health & Biotech
Health Check: Island Pharmaceuticals raises funds to put the mozz on dengue fever outbreak
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but there’s ‘wind in the sails again’
Health & Biotech